11. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/ Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133-42; PMID:11046045 12. Perrie Y, Frederik PM, Gregoriadis G. Liposome- mediated DNA vaccination: the effect of vesicle composition. Vaccine 2001; 19:3301-10; PMID: 11312029; http://dx.doi.org/10.1016/S0264-410X (00)00432-1 13. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90: 11478-82; PMID:8265577; http://dx.doi.org/10. 1073/pnas.90.24.11478 14. Haensler J, Verdelet C, Sanchez V, Girerd-Chambaz Y, Bonnin A, Trannoy E, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999; 17:628-38; PMID:10067667; http://dx. doi.org/10.1016/S0264-410X(98)00242-4 15. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, et al. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005; 11:899-904; PMID:15965482; http://dx.doi.org/10.1038/nm1264 16. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54:1-13; PMID:2700931 17. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci U S A 1999; 96:4262-7; PMID:10200250; http://dx.doi.org/10.1073/pnas.96.8.4262 18. Murakami T, Sunada Y. Plasmid DNA Gene Therapy by Electroporation: Principles and Recent Advances. Curr Gene Ther 2011; 11:447-56; PMID:22023474; http://dx.doi.org/10.2174/156652311798192860 19. Curcio C, Khan AS, Amici A, Spadaro M, Quaglino E, Cavallo F, et al. DNA immunization using constant- current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer- prone transgenic mice. Cancer Gene Ther 2008; 15:108-14; PMID:17992201; http://dx.doi.org/10. 1038/sj.cgt.7701106 20. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, et al. DNA vaccination with electropora- tion induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20:1269- 78; PMID:19619001; http://dx.doi.org/10.1089/hum. 2009.067 21. Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15:2215-22; PMID:18498012; http://dx.doi.org/10. 1245/s10434-008-9976-0 22. Quaglino E, Riccardo F, Macagno M, Bandini S, Cojoca R, Ercole E, et al. Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans. Cancers 2011; 3:3225-41; http://dx.doi.org/10.3390/ cancers3033225 23. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64:2858-64; PMID: 15087404; http://dx.doi.org/10.1158/0008-5472. CAN-03-2962 24. Amici A, Smorlesi A, Noce G, Santoni G, Cappelletti P, Capparuccia L, et al. DNA vaccination with full- length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 2000; 7:703-6; PMID:10800094; http://dx.doi.org/10. 1038/sj.gt.3301151 25. Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL, et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER- 2/neu transgenic BALB/c mice. Cancer Res 2003; 63:2518-25; PMID:12750275 26. Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, et al. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 2005; 23:3280-7; PMID:15837233; http://dx.doi.org/10.1016/j.vaccine. 2005.01.086 27. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-51; PMID:18483370; http://dx.doi. org/10.1158/1078-0432.CCR-07-4079 28. Spadaro M, Curcio C, Varadhachary A, Cavallo F, Engelmayer J, Blezinger P, et al. Requirement for IFN- gamma, CD8+ T lymphocytes, and NKT cells in talactoferrin-induced inhibition of neu+ tumors. Cancer Res 2007; 67:6425-32; PMID:17616703; http://dx.doi.org/10.1158/0008-5472.CAN-06-4080 29. Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, et al. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 2011; 19:594-601; PMID:21157438; http://dx.doi.org/10. 1038/mt.2010.268 30. Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A, Giovarelli M. Lymphokine-activated tumor inhibition in mice. Ability of a nonapeptide of the human IL-1 beta to recruit anti-tumor reactivity in recipient mice. J Immunol 1989; 142:712-8; PMID:2463312 31. Rovero S, Boggio K, Di Carlo E, Amici A, Quaglino E, Porcedda P, et al. Insertion of the DNA for the 163- 171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogen- esis in Her-2/neu transgenic BALB/c mice. Gene Ther 2001; 8:447-52; PMID:11313823; http://dx.doi.org/ 10.1038/sj.gt.3301416 32. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001; 194:1195-205; PMID: 11696586; http://dx.doi.org/10.1084/jem.194.9.1195 33. De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, et al. Immunoprevention of HER-2/ neu transgenic mammary carcinoma through an inter- leukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64:4001-9; PMID:15173014; http://dx.doi. org/10.1158/0008-5472.CAN-03-2984 34. De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, et al. A multi-DNA pre- ventive vaccine for p53/Neu-driven cancer syndrome. Hum Gene Ther 2009; 20:453-64; PMID:19215191; http://dx.doi.org/10.1089/hum.2008.172 35. Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, et al. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. Clin Cancer Res 2009; 15:641-9; PMID:19147770; http:// dx.doi.org/10.1158/1078-0432.CCR-08-1988 36. Bolli E, Quaglino E, Arigoni M, Lollini PL, Calogero R, Forni G, et al. Oncoantigens for an immune prevention of cancer. Am J Cancer Res 2011; 1:255-64; PMID:21969087 37. Grant EP, Michalek MT, Goldberg AL, Rock KL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol 1995; 155:3750-8; PMID:7561079 38. Rodriguez F, Harkins S, Redwine JM, de Pereda JM, Whitton JL. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope- specific lysosomal targeting. J Virol 2001; 75:10421- 30; PMID:11581410; http://dx.doi.org/10.1128/JVI. 75.21.10421-10430.2001 39. Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, et al. HER2-based recombinant immunogen to target DCs through FccRs for cancer immunotherapy. J Mol Med (Berl) 2011; 89:1231-40; PMID:21845448; http://dx.doi.org/10.1007/s00109- 011-0794-7 40. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, et al. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res 2008; 14:6933-43; PMID:18980988; http://dx.doi.org/10.1158/1078-0432.CCR-08-1257 41. Rolla S, Marchini C, Malinarich S, Quaglino E, Lanzardo S, Montani M, et al. Protective immunity against neu-positive carcinomas elicited by electropora- tion of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther 2008; 19:229-40; PMID:18269312; http://dx.doi.org/10. 1089/hum.2006.196 42. Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66:7734-40; PMID:16885376; http://dx.doi. org/10.1158/0008-5472.CAN-06-1432 43. Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. J Immunol 2010; 184:6124-32; PMID:20435927; http://dx.doi.org/10. 4049/jimmunol.0901215 44. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak- Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature 2011. In press. PMID:22121024; http://dx.doi.org/10.1038/ nature10664 45. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010; 70:2604-12; PMID:20332241; http://dx.doi.org/10. 1158/0008-5472.CAN-09-2548 46. Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006; 240:96-106; PMID: 16930573; http://dx.doi.org/10.1016/j.cellimm.2006. 07.002 47. Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, et al. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010; 70:119-28; PMID:20048073; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-2554 48. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID: 12407406; http://dx.doi.org/10.1038/ni1102-991 49. Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, et al. Frequent loss of HLA- A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2- restricted HER-2/neu-specific immunity. Cancer Res 2006; 66:6387-94; PMID:16778217; http://dx.doi. org/10.1158/0008-5472.CAN-06-0029 324 OncoImmunology Volume 1 Issue 3